FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.
Also in this 8-page issue: Cooperative groups tell Congress that NCI’s $115 million in support for adult cancer clinical trials is “chump change.” Trials would close faster, report results sooner, if funding were increased, regulatory issues streamlined.
Larry Norton wins ASCO’s Karnofsky award.
Funding opportunities listed.
May issue of Business & Regulatory Report, 8 additional pages, included.
Trending Stories
- As Trump’s second term nears, Republican support for NIH is at a low point
By stonewalling GOP in the House, Biden’s HHS officials eroded bipartisan support for biomedical research - As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer
- Trump 2016: A look back at the 45th president’s impact on oncology
- Cedars-Sinai spearheads first national certification program for COE staff at cancer centers
- Menin inhibitors emerge as new treatment for advanced AML
- Patient navigation benefits health systems, improves care
Initial data presented at the White House come a year after CMS payment began